Marksans Pharma Ltd. has announced its financial results for the fiscal year ending March 31, 2026, achieving a record total income of ₹3,033 crore. This marks a 12.8% increase compared to the previous year. The company’s EBITDA reached ₹601 crore, maintaining a margin of 20.4%, while the profit after tax (PAT) soared to an all-time high of ₹420 crore.
The growth was driven by a series of new product launches across various markets, including a strong performance in the UK, which saw its highest-ever quarterly revenue in Q4. The US market contributed significantly with 112 new SKUs launched during the year, enhancing Marksans Pharma‘s footprint in North America. Additionally, the company expanded into new territories such as Germany, Canada, and Ireland.
In Q4FY26, Marksans Pharma reported a total income of ₹891 crore, a 23.1% year-on-year increase. The gross profit for the quarter stood at ₹466 crore, up by 21.5% year-on-year, with a gross margin of 54.4%. The EBITDA for the quarter was ₹195 crore, with a margin of 22.8%, and earnings per share (EPS) were ₹3.3.
The US and North America formulation business generated revenues of ₹406 crore in Q4FY26 and ₹1,533 crore for the full year. The UK and Europe formulation business reported revenues of ₹308 crore in Q4 and ₹1,015 crore for FY26. The Australian and New Zealand markets also showed robust growth, with revenues reaching ₹123 crore in Q4FY26 and ₹303 crore for the year.
Despite geopolitical disruptions affecting the Rest of World (RoW) markets, Marksans Pharma maintained a strong cash balance of ₹990 crore as of March 31, 2026. The company generated ₹458 crore in cash from operations and incurred a capital expenditure of ₹131 crore during the year.
Marksans Pharma’s R&D expenditures amounted to ₹89 crore, representing 3.0% of its consolidated revenue. The company continues to focus on strengthening its product pipeline, with 18 products approved and 30 filings completed in FY26.
An earnings conference call is scheduled for May 27, 2026, at 4:30 pm IST, where the leadership team will discuss the financial performance and address questions.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).